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Abstract  
BACKGROUND: Diabetes mellitus is a progressive disorder that often requires combination therapy.  
AIM: This study aimed to compare and study of add-on sitagliptin versus pioglitazone in patients with type 2 
diabetes inadequately controlled with metformin. 
METHODS: This 12-week, randomised, open-label and single centre study compared sitagliptin (100 mg daily, n 
= 80) and pioglitazone (30 mg daily, n = 80) in type 2 diabetic patients whose disease was not adequately 
controlled with metformin. 
RESULTS: The mean change in HbA1c from baseline was -1.001 ± 0.83 with sitagliptin and -0.75 ± 1.20 with 
pioglitazone, and there were no significant difference between groups (P = 0.132). The mean change in fasting 
blood sugar (FBS) was -18.48 ± 33.32 mg/dl with sitagliptin and -20.53 ± 53.97 mg/dl with pioglitazone, and there 
were no significant difference between groups (P = 0.773). Sitagliptin caused 1.08 ± 2.39 kg decrease in weight, 
whereas pioglitazone caused 0.27 ± 2.42 kg increase in weight, with a between-group difference of 0.81 kg (P < 
0.001). On the other hand, in sitagliptin group, there was greater improvement in lipid profile than pioglitazone 
group. 
CONCLUSION: Sitagliptin and Pioglitazone demonstrated similar improvements in glycemic control in type 2 
diabetes mellitus patients whose diabetes had been inadequately controlled with metformin. Nevertheless, 
sitagliptin was more effective than pioglitazone regarding lipid and body weight change. 
 
 
 
Introduction 
 
Due to the progressive decline in the function 
of pancreatic beta cells and chronic insulin resistance 
in patients with type 2 diabetes mellitus (T2DM), 
hyperglycemia increases over time in this group of 
patients [1, 2]. Several studies have demonstrated 
that hyperglycemia is one of the major risk factors in 
the development of microvascular complications in 
T2DM patients [3, 4]. On the other hand, clinical trials 
have shown that reduction in HbA1c can decrease the 
development of T2DM complications [5, 6]. For 
instance, every one percent HbA1c decrease is 
associated with Thirty- five percent decrease in risk of 
microvascular complications [7]. American Diabetes 
Association (ADA) recommended lowering the HbA1c 
to less than 7% in T2DM patients [8, 9]. Due to the 
complex nature and multiple metabolic defects of this 
disease, treatment with a single oral 
antihyperglycemic agent is not sufficient for reaching 
the desired goal, hence combination drug therapy is 
usually required to manage patients with T2DM [6, 8, 
10, 11]. It should be noted that combination therapy 
with oral drugs requires the use of anti-hyperglycemic 
drugs with different complementary physiologic 
mechanisms to improve glycemic control [12]. 
Moreover, Beta-cell failure occurs long before 
T2DM is diagnosed and by this time, diabetic subjects 
have lost over 80% of their beta cell function. So, 
early treatment with anti-hyperglycemic drugs in 
diabetic patients can have positive effects on the 
preservation of residual pancreatic beta cells function 
[7, 8]. 
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America Diabetes Association (ADA) and 
European Association for the Study of Diabetes 
(EASD) recommend metformin as a first line drug in 
the treatment of diabetic patients, because metformin 
is inexpensive, does not cause weight gain, has 
proven safety records and probably beneficial effects 
on the cardiovascular system. Sulphonylureas, 
thiazolidinediones and dipeptidyl peptidase 4 (DPP-4) 
inhibitors have also been recommended as an 
alternative treatment or in combination therapy with 
metformin in the ADA/EASD consensus [4, 13]. 
Metformin is a drug that can reduce Hb1Ac by 
increasing liver and peripheral tissue sensitivity to 
glucose, prevent hepatic gluconeogenesis and 
glycogenolysis. This reduction in Hb1Ac is about 1.2-
3%, but metformin does not prevent beta cell failure, 
and after an initial decrease, HbA1c rises 
progressively [7, 14, 15]. 
Pioglitazone is one of the thiazolidinediones. 
Thiazolidinediones are Peroxisome Proliferator-
Activated Receptor γ (PPAR- γ) agonists and are 
appropriate for use as monotherapy and in 
combination with metformin and/or a sulphonylurea in 
patients with T2DM [16,17]. Thiazolidinediones can 
decrease insulin resistance by increasing the 
sensitivity of muscle, liver, and adipose tissue to 
insulin. These drugs delay the progression of T2DM 
and can improve beta cell function and create a 
sustainable reduction in Hb1Ac [7, 18, 19]. 
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) 
inhibitor that can affect the path of incretin hormones 
including Glucagon-Like Peptide 1 (GLP-1) and 
Glucose-dependent Insulin releasing Polypeptide 
(GIP). These hormones are secreted by the intestine 
endocrine cells in response to a meal. GLP-1 and GIP 
stimulate insulin secretion (in a glucose-dependent 
manner) and delay gastric emptying. Also, GLP-1 can 
affect pancreatic alpha cells and inhibit glucagon 
secretion. Within some minutes after the release of 
these hormones, GIP and GLP-1 undergo rapid 
metabolism to inactive metabolites by the enzyme 
DPP-4, hence sitagliptin by inhibiting this enzyme 
causes an increase in the duration of validity of 
hormones in the blood [2, 8, 10, 17]. 
As earlier mentioned, Metformin, Pioglitazone 
and sitagliptin each possess different but 
complementary mechanisms of action. Therefore, we 
can use these drugs together as a combination 
therapy [2, 12, 20]. 
The aim of the present study was to compare 
the efficacy of dual anti-hyperglycemic combination 
therapy in T2DM patients, to find the most efficient 
and effective method for treating these patients. 
 
 
 
Materials and Methods 
 
Study design 
This open-label, single centre and 
randomised control trial (code: 
IRCT2015061619554N4) were done between January 
2016 and January 2017 in vali-e-asr hospital under 
the approval of Zanjan Metabolic Disease Research 
Center (ZMDRC), Zanjan University of Medical 
Sciences. 
This study was approved by the ethics 
committee of Zanjan University of Medical Sciences. 
 
Patients 
Eligible patients were men and women, 30-60 
years of age with T2DM and inadequate glycemic 
control (HbA1c ≥8 and ≤9.5) while being actively 
treated with metformin. Their body mass index (BMI) 
was between 25-35. 
Patients with an history of ketoacidosis, 
unstable or rapidly progressive diabetic retinopathy, 
nephropathy, neuropathy, impaired hepatic function 
(defined as plasma aminotransferase level three times 
higher than the upper limit of normal for age and sex), 
impaired renal function (defined as serum creatinine 
level higher than the upper limit of normal for age and 
sex), impaired digestive function (vomiting, diarrhea, 
dyspepsia), a serious cardiovascular disease with 
ejection fraction less than 35%, pregnant women, 
breastfeeding women and women planning for 
pregnancy were excluded. All patients provided 
written informed consent to participate in the study. 
 
Treatment 
One hundred and sixty (160) T2DM patients 
were randomly assigned in a 1:1 ratio to one of the 
following treatment groups by permuted block method 
using a central computer-based randomisation (Figure 
1). 
The first group: those treated with sitagliptin 
100 mg/day in addition to their usual doses of 
metformin for 12 weeks. 
The second group: those treated with 
pioglitazone 30 mg/day in addition to their usual doses 
of metformin for 12 weeks. 
All the patients were trained on the diabetic 
regimen by the nutritionist. All the individuals were 
also advised to increase their physical activity. For 
example, 3 to 5 times per week and each time for 20 
to 30 min walking briskly or cycling. Possible side 
effects of drugs were also explained to patients. 
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Figure 1: Study flowchart 
 
Assessment 
Before the study, all participants underwent 
an initial assessment that included FBS, Bs2hpp, 
HbA1c, Cholesterol, Triglyceride, HDL, BUN, Cr, AST 
and ALT in the laboratory of Vali-E-Asr Hospital. 
Blood pressure was measured using a manometer, 
weight by an analogue scale with an accuracy of 0.5 
kg that was calibrated every day. Every month, the 
patients were followed regarding diet, physical activity, 
proper usage of drugs and side effects of drugs. 
After three months FBS, BS2hpp, HbA1c, 
Chol, TG, HDL, BUN, Cr, AST and ALT were 
monitored in patients in the Vali-E-Asr Hospital central 
laboratory. Blood pressure and weight were also re-
measured for each patient. 
 
Statistical analysis 
For collecting data, a questionnaire was 
designed in which demographic, anthropometric and 
the laboratory data were recorded. According to the 
results of the previous study that was reported, the 
mean change in HbA1c for sitagliptin and metformin 
groups were −0.86 (−1.02, −0.69) and −0.58 (−0.76, 
−0.40) respectively, the sample size was calculated 
with the power of 80% and two-sided type 1 error rate 
of 0.05 [13]. Therefore, At least 77 patients in each 
group were needed. 
An intention-to-treat (ITT) analysis was 
performed for the 160 patients after randomisation, 
and statistical analysis was done using computer 
software SPSS version 18 (SPSS Inc, Chicago, IL, 
USA). The distribution of quantitative data was 
assessed using the Kolmogorov–Smirnov test. 
Treatment groups were compared using the Student’s 
t-test for continuous variables. Comparison of only 
qualitative data (sex) was performed using Chi-square 
test. The differences in the changes of the HbA1c 
from 0–12 weeks were also determined using a 
multivariate analysis in which treatment groups were 
considered as predictor and age, sex, weight and lipid 
profile as covariates. 
In this trial, results were presented as a mean 
± standard deviation. A p value of < 0.05 was 
considered to be statistically significant. 
 
 
Results 
 
Demographic and baseline characters 
One hundred and seventy-two patients whose 
diabetes had been inadequately controlled with 
metformin were screened for this trial. Twelve patients 
were excluded from the study because they did not 
meet the inclusion criteria. Therefore, 160 patients 
were randomly assigned to the metformin-sitagliptin or 
metformin-pioglitazone group. All of these patients 
completed the study (Figure 1). About 50% of patients 
were in the metformin plus sitagliptin group (Group 1) 
and 50% in the metformin plus pioglitazone group 
(Group 2). The mean age of Group 1 and Group 2 
was 50.70 ± 7.85 and 55.12 ± 5.85, respectively. The 
percentage of female participants in the first group 
was 57.5% and in the second group was 71.3%. 
Baseline variables in both groups are 
summarised in Table 1. 
Table 1: Baseline parameters of the patients in each group 
Variable 
MEAN ± SD 
P value Group 1 
(METFORMIN+SITAGLIPTIN) 
Group 2 
(METFORMIN+PIOGLITAZONE) 
Age (year) 50.70 ± 7.85 55.12 ± 5.85 <0.001 
FBS (mg/dl) 171.09 ± 46.41 170.26 ± 56.14 0.919 
BS2hpp (mg/dl) 276.80 ± 62.08 244.00 ± 77.73 0.004 
HbA1c (%) 8.74 ± 0.60 8.63 ± 0.64 0.25 
BUN (mg/dl) 10.30 ± 1.97 10.90 ± 3.25 0.16 
Creatinin (mg/dl) 0.94 ± 0.16 0.95 ± 0.17 0.79 
AST (U/L) 40.98 ± 37.52 27.81 ± 5.9 0.002 
ALT (U/L) 40.89 ± 28.19 26.60 ± 6.42 <0.001 
TG (mg/dl) 168.38 ± 80.76 176.74 ± 106.43 0.57 
Chol (mg/dl) 177.00 ± 46.51 176.49 ± 35.98 0.93 
HDL (mg/dl) 43.18 ± 8.38 43.95 ± 8.67 0.56 
Weight (kg) 74.29 ± 13.62 73.01 ± 11.49 0.52 
SBP (mmHg) 129.00 ± 18.18 121.81 ± 14.39 0.006 
DBP (mmHg) 80.00 ± 9.27 69.88 ± 7.37 <0.001 
FBS= fasting blood glucose; BS2hpp= two-hour blood glucose; HbA1c = glycosylated 
hemoglo- bin; BUN= blood urea nitrogen; AST = aspartate aminotransferase; ALT = 
alanine aminotransferase; TG = triglycerides; Chol= cholesterol; HDL = high-density 
lipoprotein; SBP= systolic blood pressure; DBP= diastolic blood pressure 
 
HbA1C 
Metformin-sitagliptin group (Group 1) and 
metformin-pioglitazone (Group 2) had similar baseline 
HbA1c level (Table 1). The mean HbA1c levels in the 
sitagliptin group ameliorated from 8.74 ± 0.60% to 
7.74 ± 0.90% (p < 0.001) (Table 2). In the pioglitazone 
group, HbA1c improved from 8.63 ± 0.64% to 7.88 ± 
1.2% (p < 0.001) (Table 3). The difference between 
the changes produced in the two groups was not 
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statistically significant (p = 0.132) (Table 4). 
At the end, when the multivariate analysis to 
eliminate the confounding effects of other variables 
including age, sex, weight and lipid profile was 
conducted, no difference was detected between the 
two treatment groups in decreasing of HbA1c levels 
before and after treatment (β = 0.059, t = 0.360, P 
value = 0.719). 
Table 2: The mean and standard deviation of variables in the 
study before and after treatment in the group treated with 
metformin and Sitagliptin (group 1) 
Variable MEAN ± SD 
P value 
Before treatment After treatment 
FBS (mg/dl) 171.09 ± 46.41 152.60 ± 42.33 <0.001 
BS2hpp (mg/dl) 276.80 ± 62.08 228.29 ± 63.18 <0.001 
HbA1c (%) 8.74 ± 0.60 7.74 ± 0.90 <0.001 
BUN (mg/dl) 10.30 ± 1.97 10.18 ± 1.99 0.55 
Creatinin (mg/dl) 0.94 ± 0.169 0.958 ± 0.15 0.48 
AST (U/L) 40.98 ± 37.52 37.99 ± 23.55 0.78 
ALT (U/L) 40.89 ± 28.19 38.14 ± 16.83 0.63 
TG (mg/dl) 168.38 ± 80.76 133.98 ± 55.38 <0.001 
Chol (mg/dl) 177.00 ± 46.51 153.31 ± 34.91 <0.001 
HDL (mg/dl) 43.18 ± 8.38 46.35 ± 12.19 0.006 
Weight (kg) 74.29 ± 13.62 73.2 ± 13.13 <0.001 
SBP (mmHg) 129.00 ± 18.18 125.50 ± 13.20 0.025 
DBP (mmHg) 80.00 ± 9.27 77.88 ± 7.41 0.012 
 
FBS 
The two treatment groups had comparable 
FBS at baseline (Table 1). The mean FBS levels in 
the sitagliptin group improved from 171.09 ± 46.41 to 
152.60 ± 42.33 (p < 0.001) (Table 2). In the 
pioglitazone group, FBS improved from 170.26 ± 
56.144 to 149.72 ± 46.66 (p < 0.001) (Table 3). The 
difference between the changes produced in the two 
groups was not statistically significant (p = 0.773) 
(Table 4). 
 
BS2hpp 
The mean changes in BS2hpp were −48.51 ± 
57.13 mg/dl with sitagliptin and −31.51 ± 54.20 mg/dl 
with pioglitazone. The difference between the 
changes produced in the two groups was not 
statistically significant (P = 0.05) (Table 4). 
Table 3: The mean and standard deviation of variables in the 
study before and after treatment in the group treated with 
metformin and pioglitazone (second group) 
Variable 
MEAN ± SD 
P value 
Before treatment After treatment 
FBS (mg/dl) 170.26 ± 56.144 149.72 ± 46.66 <0.001 
BS2hpp (mg/dl) 244.00 ± 77.73 212.49 ± 66.56 <0.001 
HbA1c (%) 8.63 ± 0.64 7.88 ± 1.20 <0.001 
BUN (mg/dl) 10.90 ± 3.25 10.80 ± 2.67 0.54 
Creatinin (mg/dl) 0.95 ± 0.17 1.005 ± 0.81 0.58 
AST (U/L) 27.81 ± 5.90 27.60 ± 6.05 0.38 
ALT (U/L) 26.60 ± 6.42 26.26 ± 6.80 0.231 
TG (mg/dl) 176.74 ± 106.43 177.59 ± 86.79 0.937 
Chol (mg/dl) 176.49 ± 35.98 171.50 ± 37.98 0.249 
HDL (mg/dl) 43.95 ± 8.67 44.12 ± 8.28 0.823 
Weight (kg) 73.01 ± 11.49 73.29 ± 11.50 0.314 
SBP (mmHg) 121.81 ± 14.39 119.09 ± 14.01 0.06 
DBP (mmHg) 69.88 ± 7.37 69.12 ± 7.78 0.397 
 
Weight 
A mean decrease in weight in Group 1 was 
1.08 ± 2.39 kg from baseline after 12 weeks, and this 
change was statistically significant (p < 0.001) (Table 
4). In contrast to this, subjects of Group 2 had a mean 
increase of 0.27 ± 2.42 kg in their weight from a 
baseline, which was not statistically significant (p = 
0.314) (Table 4). The difference between the changes 
produced in the two groups was statistically significant 
(P < 0.001) (Table 4). 
 
Lipid profile 
The two treatment groups had comparable 
TG, chol and HDL at baseline (Table 1). The mean 
TG, chol and HDL levels in the sitagliptin group 
improved from 168.38 ± 80.76 to 133.98 ± 55.38 (p < 
0.001), 177.00 ± 46.51 to 153.31 ± 34.91 (p < 0.001) 
and 43.18 ± 8.38 to 46.35 ± 12.19 (p = 0.006) (Table 
2), respectively. In the pioglitazone group, TG, chol 
and HDL levels changed from 176.74 ± 106.43 to 
177.59 ± 86.79 (p = 0.937), 176.49 ± 35.98 to 171.5 ± 
37.98 (p = 0.249) and 43.95 ± 8.67 to 44.12 ± 8.28 (p 
= 0.823), respectively (Table 3). The difference 
between the changes produced in the two groups 
regarding these parameters was statistically 
significant (Table 4). 
Table 4: The mean and standard deviation of changes in 
baseline variables after intervention in both groups 
Variable MEAN ± SD P value 
           Group 1: 
 
metformin+sitagliptin 
             Group 2: 
 
metformin+pioglitazone 
FBS (mg/dl) -18.48 ± 33.32 -20.53 ± 53.97 0.773 
BS2hpp (mg/dl) -48.51 ± 57.13 -31.51 ± 54.20 0.05 
HbA1c (%) -1.001 ± 0.83 -0.75 ± 1.20 0.132 
BUN (mg/dl) -0.125 ± 1.88 -0.10 ± 1.47 0.92 
Creatinin (mg/dl) 0.01 ± 0.13 0.055 ± 0.80 0.66 
AST (U/L) -2.99 ± 14.90 -0.21 ± 2.29 0.105 
ALT (U/L) -2.75 ± 13.02 -0.34 ± 2.50 0.106 
TG (mg/dl) -34.40 ± 52.97 0.85 ± 96.60 0.005 
Chol (mg/dl) -23.66 ± 39.33 -4.98 ± 38.39 0.003 
HDL (mg/dl) 3.17 ± 9.96 0.17 ± 6.99 0.029 
Weight (kg) -1.08 ± 2.39 0.27 ± 2.42 <0.001 
SBP (mmHg) -3.50 ± 13.69 -2.72 ± 12.75 0.71 
DBP (mmHg) -2.12 ± 7.41 -0.75 ± 7.87 0.25 
 
Other biochemical parameters 
The change in blood pressure, liver function 
tests and kidney function tests at the end of the study 
from baseline was not significant between two groups 
(P > 0.05) (Table 4). 
 
Adverse effects 
In our study, there was no significant side 
effect such as hypoglycemia, oedema of the 
extremities, gastrointestinal symptoms, liver 
complications, kidney complications, cardiac 
complications and eye complications including 
macular oedema in both combination treatment 
groups. Also, both metformin-sitagliptin and 
metformin-pioglitazone were well tolerated. 
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Discussion 
 
In this study, sitagliptin with pioglitazone in 
T2DM patients whose diabetes had been 
inadequately controlled with metformin was 
compared. This study aimed to evaluate which agent 
is preferable to an additional non-insulin antidiabetic 
drug for patients who have been uncontrolled with 
metformin. 
The results demonstrated that although 
metformin-sitagliptin and metformin-pioglitazone had a 
great impact on the reduction of HbA1c, there was no 
significant difference between two groups (P value = 
0.132). The rate of reduction of HbA1c in metformin-
sitagliptin and metformin- pioglitazone groups was 
1.001 ± 0.83 and 0.750 ± 1.20 respectively, and the 
difference between two groups was 0.26. Sung-Chen 
Liu in Taiwan achieved HbA1c reduction in metformin- 
sitagliptin group as 0.71 ± 0.12 and in the metformin-
pioglitazone group as 0.94 ± 0.12. The difference 
between two groups in this study was 0.23, and there 
was no statistically significant difference between 
them (P-value = 0.17) [21]. As can be seen, the 
response to treatment in this study was slightly better 
than Sung-Chen Liu’s study. Part of this difference 
depends on the mean age of the participants in the 
two studies. The mean age in our study was 52.91 ± 
7.25 and was about 60 years in Sung-Chen Liu’s 
study. Old age can reduce the response to treatment. 
Older patients usually have a longer duration of 
diabetes and insulin resistance in elderly patients can 
be more when compared to younger patients [22, 23]. 
All of these factors can reduce the response to 
treatment. Chawla et al. also could not find any 
statistically significant difference in HbA1c reduction 
between these two treatment groups (P-value = 
0.203) [24]. 
Takihata et al. in a study that was done in 
Japan compared these two recent combination 
therapy in T2DM patients [13]. In contrast with our 
results, they reported that in Japanese with type 2 
diabetes mellitus, sitagliptin is much more effective 
than pioglitazone. Although in their study, the 
difference between two groups was statistically 
significant (P value = 0.024), this result can be 
attributed to the lower body weight of the subjects in 
this study in comparison with our study (66.9 kg 
against 73.65 kg). Also, it can also be attributed to the 
fact that Japanese T2DM patients have lower levels of 
insulin secretion and insulin resistance than other 
races [25, 26]. 
According to our results, reduction in FBS 
was statistically significant after intervention in both 
groups, but no statistically significant difference was 
observed between treatment groups (P-value = 
0.773). Chawla and Takihata, in two separate studies 
in line with the results of our study, did not report any 
significant difference in the FBS between the two-drug 
combination [13, 24]. In contrast, Sung-Chen Liu 
reported that the combination therapy, metformin-
pioglitazone is more effective than metformin-
sitagliptin with relation to the decreased FBS from 
baseline to endpoint [21]. Studies suggest that the 
impact of pioglitazone on blood sugar is by improving 
hepatic and peripheral insulin resistance [19, 24]. 
Based on this fact and because the population in 
Sung-Chen Liu’s study were older than our study, it, 
therefore, implies their resistance to insulin may be 
higher. In this condition and due to the mechanism of 
pioglitazone function, this reason can be expected. 
There are few studies in which the effect of these two 
combination therapies on BS2hpp is compared. In this 
trial, we concluded that metformin-sitagliptin 
combination is more effective on BS2hpp. Sitagliptin 
can improve both fasting and postprandial 
hyperglycemia effectively [27, 28, 29], but pioglitazone 
improves mainly fasting hyperglycemia [30]. So with 
this description, our results are expected. 
As shown from the trial, weight gain is a well-
known consequence of pioglitazone treatment, while 
weight neutrality has been observed in sitagliptin 
studies both in monotherapy and combination therapy 
settings [31, 32]. Overweight is associated with insulin 
resistance so that weight loss can lead to 
improvements in insulin resistance and thus better 
response to treatment [33, 34]. This implies that 
weight neutrality of sitagliptin may offer a great 
advantage in T2DM management. 
It can also be seen that metformin-sitagliptin 
in comparison with metformin-pioglitazone resulted in 
a better improvement in lipid profile status. In 
treatment with sitagliptin, cholesterol and triglyceride 
showed more reduction and HDL showed more 
increase. In contrast with the results from this study, 
Takihata [13] and Chawla [24] could not find any 
significant difference between two treatment groups 
regarding lipid profile. Sung-Chen Liu reported the 
better effect of metformin- sitagliptin on triglyceride 
levels, but in this study, pioglitazone was more 
effective in increasing HDL levels [21]. Although to 
date, there is not enough evidence about the certain 
mechanisms that improve the lipid profile in patients 
treated with Sitagliptin [24, 35], part of the 
improvement in lipid profile in our study can be 
attributed to weight loss that has occurred in sitagliptin 
recipients. 
Takihata et el stated that during the study 
period, there was a statistically significant increase in 
serum creatinine level in both groups [13]. Hajime 
Meada et al. studied 1332 T2DM patients. Twenty 
percent of all these patients were treated with 
sitagliptin alone, 36% were treated in combination with 
one other drug, 31% were treated in combination with 
two other drugs, and 12% were treated in combination 
with 3 or more drugs. Eventually, they reported that 
the creatinine level was significantly increased after 
the intervention [36]. Our results showed that in both 
groups of patients, creatinine levels increased after 
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treatment. Although this finding was not statistically 
significant, it can be attributed to the smaller 
population and shorter period of treatment. Therefore, 
it seems that assessment of renal function in patients 
with these conditions is necessary. 
Also, the results from this study showed that 
sitagliptin in comparison with pioglitazone is slightly 
better in the reduction of systolic and diastolic blood 
pressure, but there was no statistically significant 
difference between two groups in our study regarding 
systolic and diastolic blood pressure reduction. 
Mechanisms by which sitagliptin causes a reduction in 
blood pressure are GLP-1 receptor-mediated 
endothelial vasodilatation by nitric oxide stimulatory 
effect, the endothelium-independent vasodilatory 
effect of GLP-1 and increased excretion of sodium in 
urine that is done by proximal tubule [37]. 
Also in this study, there was no significant 
side effect such as hypoglycemia, oedema of the 
extremities, gastrointestinal symptoms, liver 
complications, kidney complications, cardiac 
complications and eye complications including 
macular oedema in both combination treatment 
groups. In Takihata’s study, complications such as 
hypoglycemia (3.4% in the Sitagliptin group and 3.5% 
in the pioglitazone group) and gastrointestinal 
complications (5.2% in the Sitagliptin group and 1.8% 
in the pioglitazone group) were reported [13]. Some of 
these differences are due to the duration of treatment 
and antidiabetic drugs that patients were consuming 
before enrolling in the study. In our study, all patients 
were treated with metformin, and then sitagliptin or 
pioglitazone was added to the treatment, but in 
Takihata’s study, patients were treated with 
metformin, Sulphonylurea or both and then 
pioglitazone or sitagliptin were added to the treatment. 
Non-occurrence of hypoglycemia in our study can be 
attributed to treatment with only metformin. In 
Chawla’s study in line with our study, the patients 
were treated with metformin, and after enrolling in the 
study, pioglitazone or sitagliptin was added to their 
treatment. They did not report any significant side 
effects [24]. 
Furthermore in this study, unlike other 
studies, all patients were selected from those who 
were treated with only metformin. This kind of 
selection could help us to modify the effects of 
previous treatments in patients as a confounding 
variable. 
This study has various limitations. In our 
study, participants were randomly assigned to 
treatment groups, but the mean age in two groups 
was not the same so that metformin-pioglitazone 
treatment group had higher age than the metformin-
sitagliptin group. But in the multivariate model, age 
was considered as a covariate variable, hence the 
effects of these two drug regimen were compared by 
eliminating age. Another limitation of this study was 
the patients follow up period. Perhaps the time for 
follow up was not enough for some outcomes such as 
weight loss. Also, the period of treatment was too 
short to evaluate long-term glycemic control. On the 
other hand, in this study, the effects of drugs on 
insulin resistance was not evaluated. Insulin 
resistance is an important factor that can determine 
the outcomes and the rate of response to treatments 
in T2DM patients. 
Finally, it can be concluded that both drug 
combinations were effective in reducing the levels of 
HbA1C, fasting blood glucose and blood glucose two 
hours after a meal and no significant difference was 
observed between the two treatment groups in 
improving the outcomes. 
It is recommended that further long-term 
randomised control trials and multi-central studies with 
larger sample size should be carried out. In this way, 
we can provide a reference for choosing the best 
options as dual combination therapy in patients with 
type 2 diabetes and inadequate glycemic control. 
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